BAC
Bank of America Corporation
BAC has lower modeled downside risk, despite its lower overall score.
MCY
Mercury General Corporation
MCY has a slight edge over BAC overall, supported by stronger valuation.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
MCY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
MCY's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like MCY.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
MCY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.4x | $74.50 | -14% |
| Current | 7.4x | $86.41 | — |
| Forward | 7.6x | $86.41 | — |
| Fair | 10x | $119 | +37% |
| Expensive | 13x | $152 | +76% |
Historical ranges are pointers, not guarantees.
MCY has the edge over BAC in the historical PE scenario, which offers more potential upside but is not a forecast.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over MCY on the outlook, with more favorable valuation and earnings expectations.
MCY Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect MCY's revenue to grow, but its profitability to weaken.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
MCY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.41 | -1.7% |
| Q3 2026 | $11.61 | +46% |
| Q2 2026 | $16.92 | +140% |
| Q1 2026 | $15.17 | +194% |
| Q4 2025 | $9.77 | +16% |
| Q3 2025 | $7.93 | -21% |
| Q2 2025 | $7.04 | +22% |
| Q1 2025 | $5.16 | +33% |
| Q4 2024 | $8.45 | +386% |
MCY earned $11.61 per share over the past year, up 46% from the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over MCY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over MCY on profitability, with a higher operating margin.
MCY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | -13% |
| Q2 2026 | $1.7B | +14% |
| Q1 2026 | $1.5B | +10% |
| Q4 2025 | $1.5B | +12% |
| Q3 2025 | $1.6B | +3.6% |
| Q2 2025 | $1.5B | +13% |
| Q1 2025 | $1.4B | +9.4% |
| Q4 2024 | $1.4B | -0.6% |
MCY's revenue is growing: $1.4B last quarter, down 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1.7% | -24 points |
| Q2 2026 | 19% | +5.5 points |
| Q1 2026 | 15% | +26 points |
| Q4 2025 | 16% | +7.2 points |
| Q3 2025 | 22% | +3.3 points |
| Q2 2025 | 14% | +8.2 points |
| Q1 2025 | -10% | -17 points |
| Q4 2024 | 9% | -8.3 points |
MCY's operating margin was −1.7% last quarter, down 24 points from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
MCY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $372.6M | -22% |
| Q2 2026 | $201.6M | -44% |
| Q1 2026 | $308.8M | +$390.7M |
| Q4 2025 | $273.9M | +16% |
| Q3 2025 | $479.5M | +57% |
| Q2 2025 | $357.2M | +34% |
| Q1 2025 | -$81.9M | -145% |
| Q4 2024 | $236M | +9.5% |
MCY has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over MCY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
MCY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | 0% | -- |
| 3 years | 0% | +18K shares |
| 5 years | 0% | +14K shares |
| Available history | +0.1% | +29K shares |
MCY has 55M diluted shares, about the same as a year ago.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
MCY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.8x | Net Cash |
| Q2 2026 | -0.6x | Net Cash |
| Q1 2026 | -1.2x | Net Cash |
| Q4 2025 | -1.0x | Net Cash |
| Q3 2025 | -2.1x | Net Cash |
| Q2 2025 | -2.1x | Net Cash |
| Q1 2025 | -3.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
MCY has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
MCY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.0 | Neutral |
| Stochastic | 19.1 | Oversold |
MCY's weekly RSI is 34 (neutral) and its Stochastic is 19 (oversold).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
MCY PE vs Financial Services Sector
| Metric | MCY | Sector median | Relative |
|---|---|---|---|
| PE | 7.4x | 13x | 43% below |
| PE % | 32 | 63 | 31 pts below |
MCY has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
MCY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $97.7 | 12% below |
| 20 week MA | $102.7 | 16% below |
| 50 week MA | $97.3 | 11% below |
| 100 week MA | $81.9 | 5.5% above |
| 200 week MA | $63.2 | 37% above |
MCY has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
MCY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.6 | $51.8 | +6.6% |
| 2021 | $51.8 | $51.2 | -1.2% |
| 2022 | $51.2 | $33.5 | -35% |
| 2023 | $33.5 | $37.3 | +12% |
| 2024 | $37.3 | $67.0 | +80% |
| 2025 | $67.0 | $94.0 | +40% |
| 2026 YTD | $94.0 | $86.4 | -8% |
MCY has the edge over BAC on returns for 2026, with the stronger performance.